ImmuPharma ‘Lupuzor could very quickly gain traction’ says Life Science Division (Interview)

Life Science Division Executive Director and Head of Research Dr Navid Malik joins DirectorsTalk to discuss ImmuPharma plc (LON: IMM). Navid provides an overview of the Life Science Division and how long its been following ImmuPharma, explains how he reads into the agreement with Avion, confidence for securing other deals with European partners, more details around the increase in target price from 76p to 100p, key differentiators, key milestones that will increase share price and how the sector in 2020 could benefit the company.

The Life Sciences Division (TLSD) based in London, is an independent investment bank providing advisory services to companies and investors in the life sciences sector. Its clients include companies that harness disruptive technologies such as cell therapies, gene therapies, microbiome companies, oncolytic virus technologies, artificial intelligence and digital technologies. Companies that are developing 3rd generation assets in diagnostics and drugs such as immunotherapies. With novel real-time imaging modalities, precision medicine, drug-device combinations in the area of plasma physics, and highly novel immune-therapy businesses spanning both oncology and auto-immune disease. TLSD, provides corporate finance, corporate broking and corporate research – aiming to accelerate the healthcare revolution and create greater clinical value and better patient outcomes.

ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The company portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Share this interview

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on whatsapp
Immupharma plc
ImmuPharma ‘Lupuzor could very quickly gain traction’ says Life Science Division (Interview)

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions